Dexcom Reports First Quarter 2023 Financial Results

SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended March 31, 2023.

First Quarter 2023 Financial Highlights:

• Revenue grew 18% versus the same quarter of the prior year to $741.5 million on a reported basis and 19% on an organic¹ basis.
• U.S. revenue growth of 17% and international revenue growth of 21% on a reported basis. International revenue growth was 27% on an organic¹ basis.
• GAAP operating income of $47.2 million or 6.4% of revenue, a decrease of 20 basis points compared to the first quarter of 2022. Non-GAAP operating income* of $78.6 million or 10.6% of reported revenue, an increase of 260 basis points compared with the same quarter of the prior year.

First Quarter 2023 Strategic Highlights:

• Initiated the launch of Dexcom G7 in the United States, bringing the industry’s most accurate² CGM to the company’s largest market
• Broadcasted the company’s second-ever Super Bowl commercial starring Nick Jonas to announce the arrival of G7 in the United States and promote greater awareness of CGM technology
• Finalized coverage for Dexcom G7 with the US Centers for Medicare & Medicaid Services, providing Medicare beneficiaries reimbursed access to Dexcom’s latest generation technology
• Published annual Sustainability Report, which provided enhanced reporting on the company’s environmental initiatives and significant additions to human capital disclosure

“Dexcom is off to a great start in 2023, executing on several key initiatives including the launch of Dexcom G7 in the United States,” said Kevin Sayer, Dexcom’s chairman, president and CEO. “Given the strength of our first quarter results and an expanding market opportunity with new CGM coverage now available, we are pleased to raise our 2023 revenue guidance.”

2023 Annual Guidance

The company is updating fiscal year 2023 revenue guidance, and reiterating guidance for Non-GAAP Gross Profit Margin, Non-GAAP Operating Margin and Adjusted EBITDA Margin at the following levels:

• Revenue of approximately $3.400 - 3.515 billion (17-21% growth)
• Non-GAAP Gross Profit Margin of 62-63%
• Non-GAAP Operating Margin of approximately 16.5%
• Adjusted EBITDA Margin of approximately 26%

First Quarter 2023 Financial Results

Revenue: In the first quarter of 2023, worldwide revenue grew 18% to $741.5 million on a reported basis, up from $628.8 million in the first quarter of 2022. Volume growth in conjunction with strong new customer additions continues to be the primary driver of revenue growth as awareness of real-time CGM increases.

Gross Profit: GAAP gross profit totaled $462.6 million or 62.4% of revenue for the first quarter of 2023, compared to $398.1 million or 63.3% of revenue in the first quarter of 2022.

Non-GAAP gross profit* totaled $469.8 million or 63.4% of revenue for the first quarter of 2023, compared to $398.1 million or 63.3% of reported revenue in the first quarter of 2022.

Operating Income: GAAP operating income for the first quarter of 2023 was $47.2 million, compared to GAAP operating income of $41.3 million for the first quarter of 2022.

Non-GAAP operating income* for the first quarter of 2023 was $78.6 million, compared to non-GAAP operating income of $50.3 million for the first quarter of 2022.

Net Income and Net Income Per Share: GAAP net income was $48.6 million, or $0.12 per diluted share, for the first quarter of 2023, compared to GAAP net income of $97.3 million, or $0.23 per diluted share, for the same quarter of 2022.

Non-GAAP net income* was $68.5 million, or $0.17 per diluted share, for the first quarter of 2023, compared to non-GAAP net income of $32.3 million, or $0.08 per diluted share, for the same quarter of 2022. The first quarter 2023 non-GAAP amount excludes $1.1 million of business transition and related costs, $21.3 million of intellectual property litigation costs, $9.0 million of amortization of intangible assets, and $11.5 million of tax adjustments.

Cash and Liquidity: As of March 31, 2023, Dexcom held $2.57 billion in cash, cash equivalents and marketable securities and our revolving credit facility remains undrawn. The cash balance represents significant financial and strategic flexibility as Dexcom continues to expand production capacity and explore new market opportunities.

* See Table E below for a reconciliation of these GAAP and non-GAAP financial measures.

Conference Call

Management will hold a conference call today starting at 4:30 p.m. (Eastern Time). The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom Investor Relations website at investors.dexcom.com by navigating to “Events and Presentations,” and will be archived for future reference. To listen to the conference call, please dial (888) 414-4585 (US/Canada) or (646) 960-0331 (International) and use the conference id “9430114” approximately five minutes prior to the start time.

Statement Regarding Use of Non-GAAP Financial Measures

This press release and the accompanying tables include non-GAAP financial measures. For a description of these non-GAAP financial measures, including the reasons management uses each measure, and reconciliations of these non-GAAP financial measures to the most directly comparable financial measures prepared in accordance with Generally Accepted Accounting Principles (GAAP), please see the section of the accompanying tables titled “About Non-GAAP Financial Measures” as well as the related Table E. We have not reconciled our total revenue, Non-GAAP Gross Profit Margin, Non-GAAP Operating Margin and Adjusted EBITDA Margin estimates for fiscal year 2023 because certain items that impact these figures are uncertain or out of our control and cannot be reasonably predicted. Accordingly, a reconciliation of total revenue, Non-GAAP Gross Profit Margin, Non-GAAP Operating Margin and Adjusted EBITDA Margin is not available without unreasonable effort.

About DexCom, Inc.

DexCom, Inc. empowers people to take control of diabetes through innovative continuous glucose monitoring (CGM) systems. Headquartered in San Diego, California, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of users, caregivers, and providers, Dexcom simplifies and improves diabetes management around the world. For more information about Dexcom CGM, visit www.dexcom.com.

Cautionary Statement Regarding Forward Looking Statements

This press release contains forward-looking statements that are not purely historical regarding Dexcom’s or its management’s intentions, beliefs, expectations and strategies for the future, including those related to Dexcom’s estimated total revenue, Non-GAAP Gross Profit Margin, Non-GAAP Operating Margin, and Adjusted EBITDA Margin for fiscal 2023, as well as expected growth rates as compared to the year ended December 31, 2022. All forward-looking statements included in this press release are made as of the date of this release, based on information currently available to Dexcom, deal with future events, are subject to various risks and uncertainties, and actual results could differ materially from those anticipated in those forward-looking statements. The risks and uncertainties that may cause actual results to differ materially from Dexcom’s current expectations are more fully described in Dexcom’s Annual Report on Form 10-K for the period ended December 31, 2022, as filed with the Securities and Exchange Commission (SEC) on February 9, 2023, and our most recent Quarterly Report on Form 10-Q for the quarter ended March 31, 2023, as filed with the SEC on April 27, 2023. Except as required by law, Dexcom assumes no obligation to update any such forward-looking statement after the date of this report or to conform these forward-looking statements to actual results.

ABOUT NON-GAAP FINANCIAL MEASURES

The accompanying press release dated April 27, 2023 contains non-GAAP financial measures. These non-GAAP financial measures include organic revenue, non-GAAP gross profit, non-GAAP operating income (loss), non-GAAP net income (loss), and non-GAAP net income (loss) per share as well as adjusted EBITDA.

We use these non-GAAP financial measures for financial and operational decision making and as a means to evaluate period-to-period comparisons. We believe that they provide useful information about operating results, enhance the overall understanding of our operating performance and future prospects, and allow for greater transparency with respect to key metrics used by senior management in our financial and operational decision making. Our non-GAAP financial measures exclude amounts that we do not consider part of ongoing operating results when planning and forecasting and when assessing the performance of the organization and our senior management. We compute non-GAAP financial measures using the same consistent method from quarter to quarter and year to year. We may consider whether other significant items that arise in the future should be excluded from our non-GAAP financial measures.

We report non-GAAP financial measures in addition to, and not as a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. These non-GAAP financial measures are not based on any comprehensive set of accounting rules or principles, differ from GAAP measures with the same names, and may differ from non-GAAP financial measures with the same or similar names that are used by other companies. We believe that non-GAAP financial measures should only be used to evaluate our results of operations in conjunction with the corresponding GAAP financial measures. We encourage investors to carefully consider our results under GAAP, as well as our supplemental non-GAAP information and the reconciliations between these presentations, to more fully understand our business.

Management believes organic revenue is a meaningful metric to investors as it provides a more consistent comparison of the company’s revenue to prior periods as well as to industry peers. We exclude the following items from the non-GAAP financial measure for organic revenue:

• The effect of non-CGM revenue acquired or divested in the trailing twelve months.
• The effect of foreign currency fluctuations.

Management believes that presentation of operating results that excludes these items provides useful supplemental information to investors and facilitates the analysis of our core operating results and comparison of operating results across reporting periods. Management also believes that this supplemental non-GAAP information is therefore useful to investors in analyzing and assessing our past and future operating performance.

These non-GAAP measures may be different from non-GAAP measures used by other companies. In addition, these non-GAAP measures are not based on any comprehensive set of accounting rules or principles. We believe that non-GAAP measures have limitations in that they do not reflect all of the amounts associated with our results of operations as determined in accordance with U.S. GAAP and that these measures should only be used to evaluate our results of operations in conjunction with the corresponding GAAP measures. We encourage investors to carefully consider our results under GAAP, as well as our supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand our business.

Table E reconciles the non-GAAP financial measures in the press release to the most directly comparable financial measures prepared in accordance with Generally Accepted Accounting Principles (GAAP).

We exclude the following items from non-GAAP financial measures for non-GAAP gross profit, non-GAAP operating income (loss), non-GAAP net income (loss), and non-GAAP net income (loss) per share:

• Amortization of acquired intangible assets
• Business transition and related costs associated with acquisition, integration and business transition activities, including severance, relocation, consulting, leasehold exit costs, third party merger and acquisition costs, and other costs directly associated with such activities
• COVID-19 costs associated with the COVID-19 outbreak related to taking the necessary precautions for essential personnel to operate safely both in person as well as remotely. Costs incurred include items like incremental payroll costs, consulting support, IT infrastructure and facilities related costs
• Income or loss from equity investments
• Intellectual property litigation costs
• Litigation settlement costs
• Loss on extinguishment of debt associated with our senior convertible notes
• Adjustments related to taxes for the excluded items above, as well as excess benefits or tax deficiencies from stock-based compensation, and the quarterly impact of other discrete items

Adjusted EBITDA excludes non-cash operating charges for share-based compensation, depreciation and amortization as well as non-operating items such as interest income, interest expense, loss on extinguishment of debt, income and loss from equity investments, and income tax expense or benefit. For the reasons explained above, adjusted EBITDA also excludes business transition and related costs, COVID-19 costs, litigation settlement costs, and intellectual property litigation costs.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230427005220/en/